Author:
Park Joseph P.,Jung Byoungin,Park Hyung Ki,Shin Donghoon,Jung Jin Ah,Ghil Jeehoon,Han Jihyun,Kim Kyung Ah,Woollett Gillian R.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference50 articles.
1. US FDA. “What are “biologics” questions and answers”. https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers. Accessed 11 Feb 2022.
2. Patel BN, Audet PR. A review of approaches for the management of specialty pharmaceuticals in the United States. Pharmacoeconomics. 2014;32:1105–14. https://doi.org/10.1007/s40273-014-0196-0.
3. Avalere. Use of step through policies for competitive biologics among commercial US insurers. 2018. https://img04.en25.com/Web/AvalereHealth/%7B693465f5-4dad-4776-95f4-f2ad009a49b1%7D_Use_of_Step_Through_Policies_for_Competitive_Biologics_Among_Commercial_US_Insurers.pdf. Accessed 11 Feb 2022.
4. Stucke ME. Is competition always good? J Antitrust Enforce. 2013;1(1):162–97. https://doi.org/10.1093/jaenfo/jns008.
5. US FDA. Implementation of the Biosimilars Price Competition and Innovation Act of 2009. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009. Accessed 11 Feb 2022.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献